A client received idarucizumab for life-threatening bleeding while taking dabigatran. 12 hours later, bleeding resumes and the diluted thrombin time is again prolonged. Which action is appropriate?

1 Assume reversal must remain complete for several days.
2 Restart dabigatran immediately despite active bleeding.
3 Give vitamin K because it directly neutralizes dabigatran.
4 Notify the team urgently because dabigatran effect can recur and an additional idarucizumab dose may be considered for recurrent clinically relevant bleeding. ✓ Correct answer

Explanation

Dabigatran concentrations can rebound after idarucizumab as drug redistributes, particularly with renal impairment. Recurrent bleeding with renewed coagulation prolongation requires urgent reassessment and may justify another 5-g dose.

Next question on this topicA nurse is reviewing the morning lab results for an adult client receiving warfarin for at…

In-depth explanation

Quick answer
After idarucizumab, watch for dabigatran rebound and recurrent bleeding.

Why this is correct
Vitamin K reverses vitamin-K antagonists, not the direct thrombin inhibitor dabigatran.

Easy analogy or mental picture
Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.

Memory hook
Drug, urgent cue, protective action, and reassessment endpoint.

NCLEX decision rule
Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.

Why the other choices are wrong
Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.

References

1DailyMed: PRAXBIND (idarucizumab)Recurrent dabigatran activity and consideration of a second dose

Clinical scenario

Medication-safety review
Verify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.

Browse all questions No login required

Master the NCLEX-RN with MyMerci

Thousands of NCLEX-style questions with detailed rationale — in your language. Track your progress and study smarter.

Start for free

App Store Google Play

Read in another language: English 한국어 日本語繁體中文 Tiếng Việt

For study reference only. Always follow current clinical guidelines and your institution’s protocols.

성장을 멈추지 마세요

A client received idarucizumab for life-threatening bleeding while taking dabigatran. 12 hours later, bleeding resumes and the diluted thrombin time is again prolonged. Which action is appropriate?

In-depth explanation

Clinical scenario

Master the NCLEX-RN with MyMerci